1
|
Han B, Zhang W, Li S, Wang H, Tian Y. Giant syringocystadenoma papilliferum along the Blaschko's lines. Indian J Dermatol Venereol Leprol 2024; 0:1-4. [PMID: 39152863 DOI: 10.25259/ijdvl_659_2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2023] [Accepted: 04/19/2024] [Indexed: 08/19/2024]
Affiliation(s)
- Bing Han
- Department of Dermatology and Venerology, The First Hospital of Jilin University, Changchun, Jilin Province, China
| | - Wei Zhang
- Plastic Surgery, The First Hospital of Jilin University, Changchun, Jilin Province, China
| | - Shanshan Li
- Department of Dermatology and Venerology, The First Hospital of Jilin University, Changchun, Jilin Province, China
| | - Hong Wang
- Department of Dermatology and Venerology, The First Hospital of Jilin University, Changchun, Jilin Province, China
| | - Yaping Tian
- Department of Dermatology and Venerology, The First Hospital of Jilin University, Changchun, Jilin Province, China
| |
Collapse
|
2
|
Alsugair Z, Neuhart A, Benzerdjeb N, Champagnac A, Pissaloux D, Baltres A. Sialadenoma papilliferum-like intraductal papillary tumor with unveiling BRAF V600E and PIK3CA H1047R mutations: Case report with molecular analysis and literature review. Int J Surg Case Rep 2024; 118:109611. [PMID: 38636162 PMCID: PMC11044030 DOI: 10.1016/j.ijscr.2024.109611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Revised: 03/28/2024] [Accepted: 03/31/2024] [Indexed: 04/20/2024] Open
Abstract
INTRODUCTION Sialadenoma papilliferum (SP), a rare minor salivary gland tumor, shares morphological and genetic similarities with syringocystadenoma papilliferum. Recent studies have identified BRAF V600E or HRAS mutations in SP, suggesting its neoplastic nature. Despite being uncommon, SP poses diagnostic challenges due to its resemblance to other lesions like squamous papilloma. The emergence of sialadenoma papilliferum-like intraductal papillary tumor (SP-IPT) further complicates its classification, emphasizing the need for thorough investigation. CASE PRESENTATION A 50-year-old male presented with a left palatal lesion histologically diagnosed as SP-IPT. Surgical resection revealed characteristic features, including papillary projections into cystically dilated ductal spaces. Immunohistochemistry confirmed positivity for pan-keratin AE1/AE3, cytokeratin 7, SOX10, and BRAF V600E. Whole-exome sequencing identified BRAF V600E and PIK3CA H1047R mutations. No recurrence was observed three months post-excision. DISCUSSION SP-IPT's diagnostic complexity stems from its resemblance to SP without an exophytic papillary component. However, shared BRAF mutations suggest a close relationship between the two entities. Similarities with skin adnexal tumors underscore the importance of molecular markers in tumor classification. The identification of PIK3CA mutation in SP-IPT adds to its molecular diversity, warranting further investigation into its clinical significance. CONCLUSION This study presents a case of SP-IPT with unique histological and molecular features, highlighting its diagnostic and therapeutic challenges. The co-occurrence of BRAF V600E and PIK3CA H1047R mutations suggests a distinct molecular profile in SP-IPT, necessitating further research to elucidate its biological behavior and clinical implications.
Collapse
Affiliation(s)
- Ziyad Alsugair
- Department of Pathology, Institut de Pathologie Multisite, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
| | - Anne Neuhart
- Biopathology department, Centre Leon Berard, Lyon, France
| | - Nazim Benzerdjeb
- Department of Pathology, Institut de Pathologie Multisite, Groupement Hospitalier Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | | | - Daniel Pissaloux
- Biopathology department, Centre Leon Berard, Lyon, France; The Unit of Molecular Pathology, INSERM 1052, CNRS 5286 of Cancer Research Center of Lyon, Team Genetics, Epigenetics and Biology of Sarcomas, Université Claude Bernard Lyon 1, Lyon, France
| | - Aline Baltres
- Biopathology department, Centre Leon Berard, Lyon, France
| |
Collapse
|
3
|
Cornejo KM, Hutchinson L, O'Donnell P, Meng X, Tomaszewicz K, Shalin SC, Cassarino DS, Chan MP, Quinn TR, Googe PB, Nazarian RM. Molecular Profiling of Syringocystadenocarcinoma Papilliferum Reveals RAS-Activating Mutations. Arch Pathol Lab Med 2024; 148:215-222. [PMID: 37074845 DOI: 10.5858/arpa.2022-0474-oa] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/02/2023] [Indexed: 04/20/2023]
Abstract
CONTEXT.— Syringocystadenocarcinoma papilliferum (SCACP) is a rare adnexal carcinoma and the malignant counterpart of syringocystadenoma papilliferum (SCAP), which is commonly located on the head and neck and may arise in association with a nevus sebaceus. RAS mutations have been identified in both SCAP and nevus sebaceus. OBJECTIVE.— To evaluate the clinicopathologic and molecular features of SCACPs, which have not been previously explored. DESIGN.— We obtained 11 SCACPs from 6 institutions and reviewed the clinicopathologic features. We also performed molecular profiling using next-generation sequencing. RESULTS.— The cohort comprised 6 women and 5 men with ages ranging from 29 to 96 years (mean, 73.6 years). The neoplasms occurred on the head and neck (n = 8; 73%) and extremities (n = 3; 27%). Three tumors possibly arose in a nevus sebaceus. A total of 4 cases showed at least carcinoma in situ (adenocarcinoma, n = 3; squamous cell carcinoma [SCC], n = 1), and 7 cases were invasive (SCC, n = 5; mixed adenocarcinoma + SCC, n = 2). A total of 8 of 11 cases (73%) had hot spot mutations consisting of HRAS (n = 4), KRAS (n = 1), BRAF (n = 1), TP53 (n = 4), ATM (n = 2), FLT3 (n = 1), CDKN2A (n = 1), and PTEN (n = 1). All 4 cases with HRAS mutations occurred on the head and neck, whereas the KRAS mutation occurred on the extremity. CONCLUSIONS.— RAS-activating mutations were detected in 50% of the cases, of which most (80%) involved HRAS and occurred on the head and neck, which shows overlapping features with SCAP, supporting that a subset may arise as a result of malignant transformation and likely an early oncogenic event.
Collapse
Affiliation(s)
- Kristine M Cornejo
- From the Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts (Cornejo, Nazarian)
| | - Lloyd Hutchinson
- Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts (Hutchinson, O'Donnell, Meng, Tomaszewicz)
| | - Patrick O'Donnell
- Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts (Hutchinson, O'Donnell, Meng, Tomaszewicz)
| | - Xiuling Meng
- Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts (Hutchinson, O'Donnell, Meng, Tomaszewicz)
| | - Keith Tomaszewicz
- Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts (Hutchinson, O'Donnell, Meng, Tomaszewicz)
| | - Sara C Shalin
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas (Shalin)
| | - David S Cassarino
- Southern California Permanente Medical Group, Sunset Medical Center, Department of Pathology, Los Angeles, California (Cassarino)
| | - May P Chan
- Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan (Chan)
| | - Timothy R Quinn
- Massachusetts General Physicians Organization Dermatopathology Associates, Newton, Massachusetts (Quinn)
| | - Paul B Googe
- the Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (Googe)
| | - Rosalynn M Nazarian
- From the Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts (Cornejo, Nazarian)
| |
Collapse
|
4
|
Kervarrec T, Sohier P, Pissaloux D, de la Fouchardiere A, Cribier B, Battistella M, Macagno N. Genetics of adnexal tumors: An update. Ann Dermatol Venereol 2023; 150:202-207. [PMID: 37270318 DOI: 10.1016/j.annder.2023.03.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Accepted: 03/07/2023] [Indexed: 06/05/2023]
Abstract
Cutaneous adnexal tumors form a vast heterogeneous group that include frequent entities that are mostly benign, as well as rare tumors that are occasionally malignant. In contrast to cutaneous tumors arising from the interfollicular epidermis that develop as a result of accumulation of UV-induced DNA damage (basal cell carcinoma, squamous cell carcinoma), the oncogenesis of adnexal tumors is related to a broad spectrum of genetic mechanisms (e.g., point mutation, fusion genes, viral integration, etc.). In this setting, specific and recurrent genetic alterations have been progressively reported, and these allow better classification of these entities. For certain of them, immunohistochemical tools are now available, enabling precise integrated histological and molecular diagnosis since certain entities are linked to well-defined alterations. In this context, we aim in this review to summarize the main molecular tools currently available for the classification of adnexal tumors.
Collapse
Affiliation(s)
- T Kervarrec
- CARADERM Network, Lille, France; Department of Pathology, University Hospital Center of Tours, Tours, France.
| | - P Sohier
- CARADERM Network, Lille, France; Department of Pathology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, AP-HP Centre - University of Paris Cité, Paris, France; Faculty of Medicine, University of Paris Cité, Paris, France
| | - D Pissaloux
- Department of Pathology, Centre Léon Bérard, Lyon, France
| | | | - B Cribier
- CARADERM Network, Lille, France; Dermatology Clinic, University Hospital of Strasbourg, Hôpital Civil, Strasbourg, France
| | - M Battistella
- CARADERM Network, Lille, France; Department of Pathology, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris, AP-HP Centre - Paris 7, Paris, France
| | - N Macagno
- CARADERM Network, Lille, France; Department of Pathology, AP-HM, University Hospital of la Timone, Marseille, France; University of Aix-Marseille, INSERM U1251, MMG, Marseille, France
| |
Collapse
|
5
|
Moreno Ontalba A, Gómez Durán Á, Ruiz Cabezas L, Cidoncha Pérez E, Díaz Delgado M, Rubio Fernández A. [Cystic tubulopapillary adenoma with apocrine differentiation and BRAF V600E mutation. A case report and review of the literature]. REVISTA ESPANOLA DE PATOLOGIA : PUBLICACION OFICIAL DE LA SOCIEDAD ESPANOLA DE ANATOMIA PATOLOGICA Y DE LA SOCIEDAD ESPANOLA DE CITOLOGIA 2022; 55 Suppl 1:S64-S68. [PMID: 36075666 DOI: 10.1016/j.patol.2020.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2019] [Revised: 01/27/2020] [Accepted: 02/12/2020] [Indexed: 06/15/2023]
Abstract
Syringocystadenoma papilliferum (SCAP), tubular adenoma (TA) and hydrocystoma (HC) are benign adnexal tumors. Recently it has been suggested that these lesions belong to the same morphological spectrum: Tubulopapillary cystic adenoma with apocrine differentiation (TPCAa). BRAF and K-Ras (KRAS) mutations have been described in SCAP and TA, but not in HC. Moreover, verrucous epithelial proliferations have been observed in TPCAa. We present a case of TPCAa with BRAF V600E mutation and BRAF VE1 immunohistochemical expression in the SCAP, AT, HC and verrucous hyperplasia components.
Collapse
Affiliation(s)
- Alicia Moreno Ontalba
- Servicio de Anatomía Patológica, Complejo Hospitalario Universitario de Badajoz, Badajoz, España.
| | - Áurea Gómez Durán
- Servicio de Anatomía Patológica, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - Lismary Ruiz Cabezas
- Servicio de Anatomía Patológica, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - Esther Cidoncha Pérez
- Servicio de Anatomía Patológica, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | - Mario Díaz Delgado
- Servicio de Anatomía Patológica, Complejo Hospitalario Universitario de Badajoz, Badajoz, España
| | | |
Collapse
|
6
|
Patel S, Snyderman CH, Müller SK, Agaimy A, Seethala RR. Sinonasal mixed transitional epithelial-seromucinous papillary glandular neoplasms with BRAF p.V600E mutations - sinonasal analogues to the sialadenoma papilliferum family tumors. Virchows Arch 2022; 481:565-574. [PMID: 35715530 DOI: 10.1007/s00428-022-03359-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 05/20/2022] [Accepted: 06/07/2022] [Indexed: 11/25/2022]
Abstract
Sinonasal non-intestinal type adenocarcinoma (non-ITAC) is a heterogeneous category that may benefit from improved taxonomy. With the recognition that most non-ITAC are phenotypically seromucinous, stratification may be improved by applying salivary type morphologic criteria and molecular findings. We report two cases of papillary seromucinous adenocarcinoma with sinonasal papilloma-like surface components that show histologic and molecular features analogous to the salivary sialadenoma papilliferum family of tumors. Case 1 concerns a 50-year-old female who presented with a left anterior nasoethmoid polyp, while case 2 is that of a 74 year old female with nasal polyposis. Histologically, both cases demonstrated a surface transitional sinonasal papilloma-like component (more prominent in case 2) with a deeper bilayered glandular component showing papillary and tufted micropapillary growth of monomorphic columnar to cuboidal cells with eosinophilic cytoplasm. Case 1 also showed a deep cribriform/microcystic component. Immunostains showed a delimiting p63/p40 positive basal layer around the SOX-10 positive glandular elements, while the transitional sinonasal papilloma-like components were diffusely p63/p40 positive. Like sialadenoma papilliferum and related tumors, both cases demonstrated BRAF p.V600E mutations in both components and no other alterations. The patients remain disease free at 9 and 19 months respectively. Our cases illustrate a novel sinonasal lesion and suggest that improved morphologic and molecular categorization may refine and reduce the category of non-ITAC.
Collapse
Affiliation(s)
- Simmi Patel
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
| | - Carl H Snyderman
- Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Sarina K Müller
- Department of Otolaryngology, Head and Neck Surgery, University Hospital Erlangen, Friedrich-Alexander- Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Abbas Agaimy
- Institute of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital, Erlangen, Germany
| | - Raja R Seethala
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| |
Collapse
|
7
|
Oh KY, Cho SD, Hong SD, Lee JI, Yoon HJ. Reappraisal of tubulopapillary hidradenoma-like tumor of the mandible: Suggested change in nomenclature to reflect tumor origin. Oral Surg Oral Med Oral Pathol Oral Radiol 2022; 134:465-469. [DOI: 10.1016/j.oooo.2022.05.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 03/15/2022] [Accepted: 05/31/2022] [Indexed: 10/18/2022]
|
8
|
Kervarrec T, Pissaloux D, Poilane J, Tirode F, Tallet A, Collin C, Tallegas M, Berthon P, Gaboriaud P, Sohier P, Calonje E, Luzar B, Goto K, Cokelaere K, Lamant L, Balme B, Wild R, Neuville A, Deschamps L, Auberger E, Paumier V, Bonte H, Moulonguet I, Plantier F, Cales V, Pinsolle V, Roblet D, Dupuy F, Dallot A, Seris A, Jouary T, Houben R, Schrama D, Hesbacher S, Macagno N, Battistella M, Cribier B, Vergier B, Fouchardière A, Jullie M. Recurrent
FOXK1
::
GRHL
and
GPS2
::
GRHL
fusions in trichogerminoma. J Pathol 2022; 257:96-108. [DOI: 10.1002/path.5872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 12/14/2021] [Accepted: 01/17/2022] [Indexed: 11/07/2022]
Affiliation(s)
- Thibault Kervarrec
- Department of Pathology Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
- “Biologie des infections à polyomavirus” team, UMR INRA ISP 1282 Université de Tours Tours France
- CARADERM Network
| | - Daniel Pissaloux
- Department of Biopathology Center Léon Bérard Lyon France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer Lyon France
| | - Jeremie Poilane
- Department of Pathology Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
- Platform of Somatic Tumor Molecular Genetics Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
- Department of Pathology Centre Hospitalier Universitaire de Angers Angers France
| | - Franck Tirode
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer Lyon France
| | - Anne Tallet
- Platform of Somatic Tumor Molecular Genetics Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
| | - Christine Collin
- Platform of Somatic Tumor Molecular Genetics Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
| | - Matthias Tallegas
- Department of Pathology Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
- Platform of Somatic Tumor Molecular Genetics Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
| | - Patricia Berthon
- “Biologie des infections à polyomavirus” team, UMR INRA ISP 1282 Université de Tours Tours France
| | - Pauline Gaboriaud
- “Biologie des infections à polyomavirus” team, UMR INRA ISP 1282 Université de Tours Tours France
| | - Pierre Sohier
- CARADERM Network
- Faculté de Médecine Paris Centre Santé University of Paris Paris France
- Department of Pathology Hôpital Cochin, AP‐HP Centre‐Université de Paris Paris France
| | - Eduardo Calonje
- Department of Dermatopathology St John's Institute of Dermatology, St Thomas's Hospital London UK
| | - Boštjan Luzar
- Institute of Pathology Medical Faculty University of Ljubljana Ljubljana Slovenia
| | - Keisuke Goto
- Department of Pathology Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital Tokyo Japan
- Department of Diagnostic Pathology Shizuoka Cancer Center Hospital, Sunto Japan
- Department of Diagnostic Pathology and Cytology Osaka International Cancer Institute Osaka Japan
- Department of Dermatology Hyogo Cancer Center Akashi Japan
| | | | - Laurence Lamant
- CARADERM Network
- Department of Pathology, CHU Toulouse, Institut Universitaire du Cancer Toulouse Oncopole Université Toulouse III Paul Sabatier Toulouse France
| | - Brigitte Balme
- CARADERM Network
- Department of Pathology Centre Hospitalier Universitaire de Lyon Lyon France
| | | | - Agnes Neuville
- Contades Office of Pathological Anatomy and Cytology Strasbourg France
| | - Lydia Deschamps
- CARADERM Network
- Department of Pathology, APHP Bichat Hospital Paris France
| | - Elisabeth Auberger
- Service d'anatomie et cytologie pathologiques Hopital Simone Veil Eaubonne France
| | | | | | | | - Françoise Plantier
- Department of Pathology Hôpital Cochin, AP‐HP Centre‐Université de Paris Paris France
- Cabinet Mathurin Moreau Paris France
| | - Valérie Cales
- Department of Pathology Centre hospitalier de Pau Pau France
| | - Vincent Pinsolle
- Department of plastic and reconstructive surgery Hôpital Haut‐Lévêque, Centre hospitalier universitaire de Bordeaux Pessac France
| | - Denis Roblet
- Department of Pathology Centre hospitalier d'Angouleme Saint Michel France
| | - Frantz Dupuy
- Laboratoire de cytologie et d'anatomie pathologiques», le Bouscat France
| | - Alexiane Dallot
- Centre national de Dermatopathologie‐La Roquette Paris France
| | | | - Thomas Jouary
- CARADERM Network
- Department of Dermatology Centre Hospitalier de Pau Pau France
| | - Roland Houben
- Department of Dermatology, Venereology and Allergology University Hospital Würzburg, Josef‐Schneider‐Straße 2 Würzburg Germany
| | - David Schrama
- Department of Dermatology, Venereology and Allergology University Hospital Würzburg, Josef‐Schneider‐Straße 2 Würzburg Germany
| | - Sonja Hesbacher
- Department of Dermatology, Venereology and Allergology University Hospital Würzburg, Josef‐Schneider‐Straße 2 Würzburg Germany
| | - Nicolas Macagno
- CARADERM Network
- Department of Biopathology Center Léon Bérard Lyon France
- Department of Pathology Timone University Hospital Marseille France
| | - Maxime Battistella
- CARADERM Network
- Department of Pathology, APHP Hôpital Saint Louis Université Paris 7 Paris France
| | - Bernard Cribier
- CARADERM Network
- Dermatology Clinic, Hôpitaux Universitaires & Université de Strasbourg, Hôpital Civil Strasbourg France
| | - Beatrice Vergier
- Department of Pathology, Hôpital Haut‐Lévêque, CHU de Bordeaux Pessac France
| | - Arnaud Fouchardière
- CARADERM Network
- Department of Biopathology Center Léon Bérard Lyon France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer Lyon France
| | - Marie‐Laure Jullie
- CARADERM Network
- Department of Pathology, Hôpital Haut‐Lévêque, CHU de Bordeaux Pessac France
| |
Collapse
|
9
|
Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors. Cancers (Basel) 2022; 14:cancers14030476. [PMID: 35158743 PMCID: PMC8833812 DOI: 10.3390/cancers14030476] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 01/11/2022] [Accepted: 01/12/2022] [Indexed: 01/27/2023] Open
Abstract
Simple Summary Cutaneous sweat gland tumors form an extremely diverse and heterogeneous group of neoplasms that show histological differentiation to the sweat apparatus. Due to their rarity, wide diagnostic range, and significant morphological overlap between entities, their accurate diagnosis remains challenging for pathologists. Until recently, little was known about the molecular pathogenesis of adnexal tumors. Recent findings have revealed a wide range of gene fusions and other oncogenic factors that can be used for diagnostic purposes and, for some, can be detected by immunohistochemistry. Among other organs containing exocrine glands, such as salivary glands, breasts, and bronchi, most of these biomarkers have been reported in homologous neoplasms that share morphological features with their cutaneous counterparts. This review aims to describe these recent molecular and immunohistochemical biomarkers in the field of sweat gland tumors. Abstract Cutaneous sweat gland tumors are a subset of adnexal neoplasms that derive or differentiate into the sweat apparatus. Their great diversity, rarity, and complex terminology make their pathological diagnosis challenging. Recent findings have revealed a wide spectrum of oncogenic drivers, several of which are of diagnostic interest for pathologists. Most of these molecular alterations are represented by gene fusions, which are shared with other homologous neoplasms occurring in organs containing exocrine glands, such as salivary and breast glands, which show similarities to the sweat apparatus. This review aims to provide a synthesis of the most recent immunohistochemical and molecular markers used for the diagnosis of sweat gland tumors and to highlight their relationship with similar tumors in other organs. It will cover adenoid cystic carcinoma (NFIB, MYB, and MYBL1 fusion), cutaneous mixed tumor (PLAG1 fusion), cylindroma and spiradenoma and their carcinomas thereof (NF-κB activation through CYLD inactivation or ALKP1 hotspot mutation), hidradenoma and hidradenocarcinoma (MAML2 fusion), myoepithelioma (EWSR1 and FUS fusion), poroma and porocarcinoma (YAP1, MAML2, and NUTM1 fusion), secretory carcinoma (ETV6, NTRK3 fusion), tubular adenoma and syringo-cystadenoma papilliferum (HRAS and BRAF activating mutations). Sweat gland tumors for which there are no known molecular abnormalities will also be briefly discussed, as well as potential future developments.
Collapse
|
10
|
Plotzke JM, Adams DJ, Harms PW. Molecular pathology of skin adnexal tumours. Histopathology 2022; 80:166-183. [PMID: 34197659 DOI: 10.1111/his.14441] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Accepted: 06/30/2021] [Indexed: 11/28/2022]
Abstract
AIMS Tumours of the cutaneous adnexa arise from, or differentiate towards, structures in normal skin such as hair follicles, sweat ducts/glands, sebaceous glands or a combination of these elements. This class of neoplasms includes benign tumours and highly aggressive carcinomas. Adnexal tumours often present as solitary sporadic lesions, but can herald the presence of an inherited tumour syndrome such as Muir-Torre syndrome, Cowden syndrome or CYLD cutaneous syndrome. In contrast to squamous cell carcinoma and basal cell carcinoma, molecular changes in adnexal neoplasia have been poorly characterised and there are few published reviews on the current state of knowledge. METHODS AND RESULTS We reviewed findings in peer-reviewed literature on molecular investigations of cutaneous adnexal tumours published to June 2021. CONCLUSIONS Recent discoveries have revealed diverse oncogenic drivers and tumour suppressor alterations in this class of tumours, implicating pathways including Ras/MAPK, PI3K, YAP/TAZ, beta-catenin and nuclear factor kappa B (NF-κB). These observations have identified novel markers, such as NUT for poroma and porocarcinoma and PLAG1 for mixed tumours. Here, we provide a comprehensive overview and update of the molecular findings associated with adnexal tumours of the skin.
Collapse
Affiliation(s)
- Jaclyn M Plotzke
- Department of Pathology, University of Michigan, Ann Arbor, MI, USA
| | | | - Paul W Harms
- Department of Pathology, University of Michigan, Ann Arbor, MI, USA
- Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
11
|
Bourlond F, Battistella M, Amici JM, Dousset L, Vergier B, Beylot-Barry M, Cribier B. Clinicopathologic analysis of trichoblastoma and comparison with nodular basal cell carcinoma. Ann Dermatol Venereol 2021; 148:177-182. [PMID: 34176642 DOI: 10.1016/j.annder.2021.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 12/15/2020] [Accepted: 03/18/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Trichoblastoma (TB) is an uncommon benign follicular tumour for which clinical data is limited since most reports originate from pathology studies. OBJECTIVE To describe the clinical aspects of TB. METHODS This is an ancillary study of a prospective multicentre cohort of 2710 clinically suspected basal cell carcinoma (BCC), including 935 nodular BCCs. Sixty-two cases were TB: they were analysed and compared to 935 nodular BCCs. RESULTS TB mostly occurred in females (61% vs. 43% for BCC, P<0.01) of mean age 63 years. They were located on the head and neck, mainly on the nose and forehead, in 87% of cases. The mean size was 8.1mm, 77% were<10mm (55% of BCCs, P<0.001), 8% were ulcerated (vs. 21% of BCCs, P<0.02), and 47% persisted for more than 1 year (34% of BCCs, P<0.05). Most cases had a clinical presentation similar to nodular BCC, except for 5 small, flat, white papules and 1 anfractuous plaque. LIMITATIONS Cases originated from a series of tumours clinically suspected as BCCs. DISCUSSION Some 2.6% of tumours clinically diagnosed as BCC are in fact TB. TB occurs on the head, are more frequent in women, and are smaller and of longer duration than BCC. In most cases, clinical diagnosis on clinical grounds is difficult.
Collapse
Affiliation(s)
- F Bourlond
- Dermatology Clinic, Strasbourg University Hospitals, 1, place de l'Hôpital, 67091 Strasbourg, France.
| | - M Battistella
- Pathology Department, Saint-Louis Hospital AP-HP, Paris University, INSERM U976, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - J-M Amici
- Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33000 Bordeaux, France
| | - L Dousset
- Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33000 Bordeaux, France
| | - B Vergier
- Anatomic Pathology Department, Bordeaux University Hospital, Haut-Lévêque Hospital, avenue du Haut-Lévêque, 33604 Pessac, France
| | - M Beylot-Barry
- Dermatology Department, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33000 Bordeaux, France; Inserm U1053, 146, rue Léo-Saignat, 33000 Bordeaux, France
| | - B Cribier
- Dermatology Clinic, Strasbourg University Hospitals, 1, place de l'Hôpital, 67091 Strasbourg, France
| |
Collapse
|
12
|
Hile G, Harms PW. Update on Molecular Genetic Alterations of Cutaneous Adnexal Neoplasms. Surg Pathol Clin 2021; 14:251-272. [PMID: 34023104 DOI: 10.1016/j.path.2021.03.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Cutaneous adnexal tumors recapitulate follicular, sweat gland, and/or sebaceous epithelia, and range from benign tumors to aggressive carcinomas. Adnexal tumors can be hallmarks for inherited tumor syndromes. Oncogenic drivers of adnexal neoplasms modulate intracellular pathways including mitogen-activated protein kinase, phosphoinositide-3-kinase, Wnt/β-catenin, Hedgehog, nuclear factor κB, and Hippo intracellular signaling pathways, representing potential therapeutic targets. Malignant progression can be associated with tumor suppressor loss, especially TP53. Molecular alterations drive expression of specific diagnostic markers, such as CDX2 and LEF1 in pilomatricomas/pilomatrical carcinomas, and NUT in poromas/porocarcinomas. In these ways, improved understanding of molecular alterations promises to advance diagnostic, prognostic, and therapeutic possibilities for adnexal tumors.
Collapse
Affiliation(s)
- Grace Hile
- Department of Dermatology, University of Michigan, 1910 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5314, USA
| | - Paul W Harms
- Department of Dermatology, University of Michigan, 1910 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5314, USA; Department of Pathology, University of Michigan, 2800 Plymouth Road, Building 35, Ann Arbor, MI 48109 - 2800, USA.
| |
Collapse
|
13
|
Sorlin A, Carmignac V, Amiel J, Boccara O, Fraitag S, Maruani A, Theiler M, Weibel L, Duffourd Y, Philippe C, Thauvin-Robinet C, Faivre L, Rivière JB, Vabres P, Kuentz P. Expanding the clinical spectrum of mosaic BRAF skin phenotypes. J Eur Acad Dermatol Venereol 2021; 35:e690-e693. [PMID: 34051131 DOI: 10.1111/jdv.17413] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Accepted: 05/19/2021] [Indexed: 11/28/2022]
Affiliation(s)
- A Sorlin
- Centre de Génétique et Centre de référence « Anomalies du Développement et Syndromes Malformatifs », Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.,UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France
| | - V Carmignac
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France
| | - J Amiel
- Service de Génétique Médicale, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - O Boccara
- Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université Paris, Paris-Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - S Fraitag
- Service d'Anatomie et de Cytologie Pathologiques, APHP, Hôpital Necker-Enfants Malades, Paris, France
| | - A Maruani
- Service de Dermatologie, Centre de Référence des Maladies Rares - MAGEC, Centre Hospitalier Universitaire de Tours, Université de Tours, SPHERE-INSERM 1246, Tours, France
| | - M Theiler
- Pediatric Skin Center, Department of Dermatology, University Children's Hospital Zurich, Zurich, Switzerland
| | - L Weibel
- Pediatric Skin Center, Department of Dermatology, University Children's Hospital Zurich, Zurich, Switzerland
| | - Y Duffourd
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France
| | - C Philippe
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,UF Innovation en diagnostic génomique des maladies rares, CHU de Dijon Bourgogne, Dijon, France
| | - C Thauvin-Robinet
- Centre de Génétique et Centre de référence « Anomalies du Développement et Syndromes Malformatifs », Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.,UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France
| | - L Faivre
- Centre de Génétique et Centre de référence « Anomalies du Développement et Syndromes Malformatifs », Hôpital d'Enfants, Centre Hospitalier Universitaire de Dijon, Dijon, France.,UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France
| | - J-B Rivière
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,UF Innovation en diagnostic génomique des maladies rares, CHU de Dijon Bourgogne, Dijon, France
| | - P Vabres
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,Service de Dermatologie, Centre Hospitalier Universitaire de Dijon, Dijon, France
| | - P Kuentz
- UMR-Inserm 1231 GAD, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), Centre Hospitalier Universitaire de Dijon et Université de Bourgogne Franche-Comté, Dijon, France.,Oncobiologie Génétique Bioinformatique, PCBio, Centre Hospitalier Universitaire de Besançon, Besançon, France
| |
Collapse
|
14
|
Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation. Int J Mol Sci 2021; 22:ijms22105077. [PMID: 34064849 PMCID: PMC8151110 DOI: 10.3390/ijms22105077] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2021] [Revised: 04/15/2021] [Accepted: 05/02/2021] [Indexed: 12/16/2022] Open
Abstract
Adnexal tumors of the skin are a rare group of benign and malignant neoplasms that exhibit morphological differentiation toward one or more of the adnexal epithelium types present in normal skin. Tumors deriving from apocrine or eccrine glands are highly heterogeneous and represent various histological entities. Macroscopic and dermatoscopic features of these tumors are unspecific; therefore, a specialized pathological examination is required to correctly diagnose patients. Limited treatment guidelines of adnexal tumor cases are available; thus, therapy is still challenging. Patients should be referred to high-volume skin cancer centers to receive an appropriate multidisciplinary treatment, affecting their outcome. The purpose of this review is to summarize currently available data on pathogenesis, diagnosis, and treatment approach for apocrine and eccrine tumors.
Collapse
|
15
|
Theiler M, Weibel L, Christen-Zaech S, Carmignac V, Sorlin A, Neuhaus K, Chevarin M, Thauvin-Robinet C, Philippe C, Faivre L, Vabres P, Kuentz P. Cerebriform sebaceous nevus: a subtype of organoid nevus due to specific postzygotic FGFR2 mutations. J Eur Acad Dermatol Venereol 2021; 35:2085-2090. [PMID: 33930231 DOI: 10.1111/jdv.17319] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2021] [Revised: 03/20/2021] [Accepted: 04/13/2021] [Indexed: 12/29/2022]
Abstract
BACKGROUND Postzygotic mutations in FGFR2 have been identified in mosaic forms of acne, keratinocytic epidermal nevi, nevoid acanthosis nigricans / rounded and velvety epidermal nevus and in two fetuses with papillomatous pedunculated sebaceous nevus (PPSN). OBJECTIVES To determine the clinical and genetic characteristics of children with cerebriform, papillomatous and pedunculated variants of sebaceous nevi. METHODS Infants diagnosed with sebaceous nevi characterized by a cerebriform, papillomatous and/or pedunculated morphology over a 10-year period (2010-2019) at three paediatric dermatology centres in Switzerland and France were included in this case series. Clinical and histological characteristics were assessed. Next-generation sequencing was used to assess for FGFR2 mutations. RESULTS All nevi were located on the head, with a rounded or linear shape and a typical cerebriform, sometimes papillomatous and pedunculated, surface. No associated extracutaneous anomalies were found. Nevi harboured postzygotic mutations in the transmembrane domain of FGFR2 in 6/8 children (75%), either the known specific p.(Cys382Arg) mutation in 5 cases, or a novel mutation, p.(Val395Asp), in one. CONCLUSIONS We found an exquisite genotype-phenotype correlation in these rare nevi, with specific postzygotic mutations in the transmembrane domain of FGFR2. As not all lesions were truly papillomatous and pedunculated, the term cerebriform sebaceous nevus (CSN) appears more suitable than PPSN to describe this entity. The cerebriform pattern of CSN is reminiscent of cutis gyrata, as seen in Beare-Stevenson syndrome, which is caused by closely related germline FGFR2 mutations. While clinically impressive, CSN seem to carry a good prognosis and a low risk for extracutaneous associations.
Collapse
Affiliation(s)
- M Theiler
- Pediatric Skin Center, Department of Dermatology, University Children's Hospital Zurich, Zurich, Switzerland
| | - L Weibel
- Pediatric Skin Center, Department of Dermatology, University Children's Hospital Zurich, Zurich, Switzerland
| | - S Christen-Zaech
- Unité de Dermatologie Pédiatrique, Services de Dermatologie et de Pédiatrie, Département Femme-mère-enfant, Site de l'Hôpital de L'enfance, Lausanne, Switzerland
| | - V Carmignac
- Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France
| | - A Sorlin
- Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,Centre de Génétique Médicale, Centre de Référence "Déficiences Intellectuelles de causes rares", CHU de Dijon Bourgogne, Dijon, France
| | - K Neuhaus
- Pediatric Skin Center, Division of Plastic and Reconstructive Surgery, Department of Surgery, University Children's Hospital Zurich, Zurich, Switzerland
| | - M Chevarin
- Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France
| | - C Thauvin-Robinet
- Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,Centre de Génétique Médicale, Centre de Référence "Déficiences Intellectuelles de causes rares", CHU de Dijon Bourgogne, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), CHU de Dijon Bourgogne, Dijon, France
| | - C Philippe
- Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), CHU de Dijon Bourgogne, Dijon, France
| | - L Faivre
- Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,Centre de Génétique Médicale, Centre de Référence "Déficiences Intellectuelles de causes rares", CHU de Dijon Bourgogne, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), CHU de Dijon Bourgogne, Dijon, France
| | - P Vabres
- Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), CHU de Dijon Bourgogne, Dijon, France.,Centre de Référence Constitutif MAGEC, Service de Dermatologie, Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France
| | - P Kuentz
- Inserm UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France.,Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), CHU de Dijon Bourgogne, Dijon, France.,Oncobiologie Génétique Bioinformatique, PCBio, Centre Hospitalier Universitaire de Besançon, Besançon, France
| |
Collapse
|
16
|
Płachta I, Kleibert M, Czarnecka AM, Spałek M, Szumera-Ciećkiewicz A, Rutkowski P. Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation. Int J Mol Sci 2021; 22:4759. [PMID: 33946233 PMCID: PMC8125718 DOI: 10.3390/ijms22094759] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2021] [Revised: 04/21/2021] [Accepted: 04/23/2021] [Indexed: 12/30/2022] Open
Abstract
Neoplasms derived from follicular tissue are extremely rare. Clinically, they are reported as non-symptomatic, slow-growing nodules. These lesions are mainly benign, but the malignant type can occur. Mainly middle-aged people (50-60 years of age) are affected. These carcinomas are mainly localized on the head and neck or torso. They can be locally aggressive and infiltrate surrounding tissue and metastasize to regional lymph nodes. In the minority of cases, distant metastases are diagnosed. Quick and relevant diagnosis is the basis of a treatment for all types of tumors. The patient's life expectancy depends on multiple prognostic factors, including the primary tumor size and its mitotic count. Patients should be referred to a specialized skin cancer center to receive optimal multidisciplinary treatment. This article tries to summarize all the information that is currently available about pathogenesis, diagnosis, and treatment methods of follicular tumors.
Collapse
Affiliation(s)
- Iga Płachta
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (I.P.); (M.K.); (M.S.); (P.R.)
- Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland
| | - Marcin Kleibert
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (I.P.); (M.K.); (M.S.); (P.R.)
- Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland
| | - Anna M. Czarnecka
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (I.P.); (M.K.); (M.S.); (P.R.)
| | - Mateusz Spałek
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (I.P.); (M.K.); (M.S.); (P.R.)
| | - Anna Szumera-Ciećkiewicz
- Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland;
- Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, 00-791 Warsaw, Poland
| | - Piotr Rutkowski
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland; (I.P.); (M.K.); (M.S.); (P.R.)
| |
Collapse
|
17
|
Minowa T, Kamiya T, Hida T, Okura M, Kato J, Idogawa M, Tange S, Hirano T, Tokino T, Uhara H. Genetic analyses of a secondary poroma and trichoblastoma in a HRAS-mutated sebaceous nevus. J Dermatol 2021; 48:1268-1272. [PMID: 33908086 DOI: 10.1111/1346-8138.15919] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 04/01/2021] [Accepted: 04/03/2021] [Indexed: 11/30/2022]
Abstract
A sebaceous nevus is a congenital skin hamartoma caused by postzygotic HRAS or KRAS mosaic mutations. With age, affected individuals may develop secondary tumors within a sebaceous nevus. RAS mutations are harbored from the onset of sebaceous nevus, and further mutations can be expected to be required in order to explain the initiation of secondary tumors. However, genetic analyses of the secondary tumors have not been conducted. Herein, we describe the rare coexistence of a poroma and a trichoblastoma arising in a sebaceous nevus. This is the first report of an investigation of multiple genes in a secondary tumor in an SN. First, HRAS c.37G>C, which is the common mutation in sebaceous nevus, was detected in all three lesions (sebaceous nevus, poroma, and trichoblastoma). Next, to elucidate the potential second-hit mutations in the secondary poroma and trichoblastoma, we applied a panel sequencing for skin cancers that was newly developed in our institution. Our comparison of the mutational profile of 95 skin cancer-related genes in each of the three lesions newly revealed TP53 p.R158P in the poroma and NOTCH2 p.G329S in the trichoblastoma. TP53 p.R158P has been determined as a pathogenic mutation in other tumors, and NOTCH2 p.G329S was a novel mutation. We identified two novel mutations that may have contributed to the pathogenesis of the secondary tumor's development. The roles of the mutations remain unclear.
Collapse
Affiliation(s)
- Tomoyuki Minowa
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Takafumi Kamiya
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Tokimasa Hida
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Masae Okura
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Junji Kato
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Masashi Idogawa
- Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Shoichiro Tange
- Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Tomomi Hirano
- Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Takashi Tokino
- Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hisashi Uhara
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| |
Collapse
|
18
|
Abstract
Sialadenoma papilliferum (SP) is a rare, benign salivary gland neoplasm sharing similar histopathologic features and harboring the same genetic alterations, BRAF V600E or HRAS mutations, with syringocystadenoma papilliferum. SP most commonly occurs in the hard palate and in older adults. Clinically, SP is most likely to be diagnosed as a squamous papilloma. Microscopically, SP shows an exophytic papillary epithelial proliferation and a contiguously endophytic ductal proliferation. Two distinct subtypes are identified: classic SP and oncocytic SP. Conservative surgical treatment seems to be adequate with a low recurrence. SOX10 immunohistochemistry and BRAF analysis may be useful in differential diagnosis.
Collapse
Affiliation(s)
- Min-Shu Hsieh
- Department of Pathology, National Taiwan University Hospital, No 7, Chung-Shan South Road, Taipei 100, Taiwan; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei, Taiwan
| | - Justin A Bishop
- Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
| | - Julia Yu Fong Chang
- Department of Dentistry, National Taiwan University Hospital, No. 1, Changde Street, Zhongzheng District, Taipei City 100, Taiwan; Department of Dentistry, Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan.
| |
Collapse
|
19
|
Bawany F, Paul D, Morrison C, Scott GA, Cordisco M. A nodular growth arising on a linear lesion in an adolescent. Pediatr Dermatol 2020; 37:730-731. [PMID: 32706470 DOI: 10.1111/pde.14189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Fatima Bawany
- University of Rochester Medical Center, Rochester, New York
| | - Deborah Paul
- University of Rochester Medical Center, Rochester, New York
| | | | - Glynis A Scott
- University of Rochester Medical Center, Rochester, New York
| | - Maria Cordisco
- University of Rochester Medical Center, Rochester, New York
| |
Collapse
|
20
|
Nakaguro M, Urano M, Ogawa I, Hirai H, Yamamoto Y, Yamaguchi H, Tanigawa M, Matsubayashi J, Hirano H, Shibahara J, Tada Y, Tsuzuki T, Okada Y, Sato Y, Ikeda K, Sukeda A, Honda Y, Mikami Y, Nagao T. Histopathological evaluation of minor salivary gland papillary–cystic tumours: focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm. Histopathology 2019; 76:411-422. [DOI: 10.1111/his.13990] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 09/05/2019] [Accepted: 09/05/2019] [Indexed: 12/16/2022]
Affiliation(s)
- Masato Nakaguro
- Department of Pathology and Laboratory Medicine Nagoya University Hospital Nagoya Japan
| | - Makoto Urano
- Department of Diagnostic Pathology School of Medicine Fujita Health University Toyoake Japan
| | - Ikuko Ogawa
- Centre of Oral Clinical Examination Hiroshima University Hospital Hiroshima Japan
| | - Hideaki Hirai
- Department of Anatomical Pathology Tokyo Medical University Tokyo Japan
| | | | - Hiroshi Yamaguchi
- Department of Anatomical Pathology Tokyo Medical University Tokyo Japan
| | - Maki Tanigawa
- Department of Anatomical Pathology Tokyo Medical University Tokyo Japan
| | - Jun Matsubayashi
- Department of Anatomical Pathology Tokyo Medical University Tokyo Japan
| | - Hiroshi Hirano
- Department of Pathology Tokyo Medical University Hachioji Medical Centre Tokyo Japan
| | | | - Yuichiro Tada
- Department of Head and Neck Oncology and Surgery International University of Health and Welfare Mita Hospital Tokyo Japan
| | | | - Yasuo Okada
- Department of Pathology The Nippon Dental University School of Life Dentistry at Niigata Niigata Japan
| | - Yuichiro Sato
- Department of Head and Neck Surgery Niigata Cancer Centre Hospital Niigata Japan
| | | | - Aoi Sukeda
- Department of Anatomical Pathology Tokyo Medical University Tokyo Japan
| | - Yumi Honda
- Department of Diagnostic Pathology Kumamoto University Hospital Kumamoto Japan
| | - Yoshiki Mikami
- Department of Diagnostic Pathology Kumamoto University Hospital Kumamoto Japan
| | - Toshitaka Nagao
- Department of Anatomical Pathology Tokyo Medical University Tokyo Japan
| |
Collapse
|
21
|
Eiger-Moscovich M, Zhang PJL, Lally SE, Shields CL, Eagle RC, Milman T. Tubular apocrine adenoma of the eyelid - A case report and literature review. Saudi J Ophthalmol 2019; 33:304-307. [PMID: 31686976 PMCID: PMC6819710 DOI: 10.1016/j.sjopt.2019.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Accepted: 07/08/2019] [Indexed: 11/25/2022] Open
Abstract
Tubular apocrine adenoma is a rare benign adnexal neoplasm most commonly identified in the scalp, composed of a dermal proliferation of apocrine tubules in a background of hyalinized stroma. Tubular apocrine adenoma can be a component of various sweat gland tumors and can also morphologically overlap with other sweat gland neoplasms. Isolated tubular apocrine adenoma arising in the glands of Moll is exceedingly rare, with only 4 previously reported cases. We present a 63-year-old male with tubular apocrine adenoma of the left upper eyelid, which recurred following initial incomplete excision. Although the lesion showed focal morphologic similarity to the apocrine variant of pleomorphic adenoma (chondroid syringoma), the diagnosis of tubular apocrine adenoma was supported by fluorescence in situ hybridization studies, which demonstrated absence of PLAG1 and HMGA2 gene rearrangements seen in pleomorphic adenoma. This case illustrates the clinical, microscopic and immunohistochemical features of tubular apocrine adenoma. The recent advances in our understanding of the molecular genetics of tubular apocrine adenoma and related tumors, and how these advances shape the evolving classification of sweat gland tumors are reviewed.
Collapse
Affiliation(s)
- Maya Eiger-Moscovich
- Department of Pathology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA
| | - Paul J L Zhang
- Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA
| | - Sara E Lally
- Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA
| | - Carol L Shields
- Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA
| | - Ralph C Eagle
- Department of Pathology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA
| | - Tatyana Milman
- Department of Pathology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.,Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA
| |
Collapse
|
22
|
Alegría-Landa V, Jo-Velasco M, Santonja C, Eraña I, Vergara-Sanchez A, Kutzner H, Requena L. Syringocystadenoma papilliferum associated with verrucous carcinoma of the skin in the same lesion: Report of four cases. J Cutan Pathol 2019; 47:12-16. [PMID: 31449665 DOI: 10.1111/cup.13572] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Revised: 08/07/2019] [Accepted: 08/16/2019] [Indexed: 12/16/2022]
Abstract
The association of syringocystadenoma papilliferum (SCAP) with verrucous carcinoma (VC) of the skin in the same lesion is a rare, but well-documented event. Although human papillomaviruses (HPV) have been proposed to have an etiologic role in the development of the verrucous proliferations associated with SCAP, most of the immunohistochemical and molecular studies have failed to show the presence of their genomic material in these lesions. We report a series of four cases of SCAP associated with VC in anogenital lesions. In two of the cases, we demonstrated the presence of the BRAF V600E mutation by polymerase chain reaction and immunohistochemistry, both in the glandular and in the squamous component. No HPV-related histopathologic changes were found, nor could the presence of viral DNA be showed.
Collapse
Affiliation(s)
| | - Margarita Jo-Velasco
- Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | - Carlos Santonja
- Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | - Itziar Eraña
- Department of Pathology, Hospital de Guadalajara, Universidad de Alcalá de Henares, Guadalajara, Spain
| | - Aranzazú Vergara-Sanchez
- Department of Dermatology, Hospital de Guadalajara, Universidad de Alcalá de Henares, Guadalajara, Spain
| | - Heinz Kutzner
- Dermatopathologie Laboratory, Friedrichshafen, Germany
| | - Luis Requena
- Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| |
Collapse
|
23
|
Syringocystadenoma Papilliferum of the Anogenital Area and Buttocks: A Report of 16 Cases, Including Human Papillomavirus Analysis and HRAS and BRAF V600 Mutation Studies. Am J Dermatopathol 2019; 41:281-285. [PMID: 30398985 DOI: 10.1097/dad.0000000000001285] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Syringocystadenoma papilliferum (SCAP) is a benign tumor most commonly located on the head and neck area often associated with nevus sebaceus. In its usual location, the human papillomavirus (HPV) DNA and mutations in the RAS/mitogen-activated protein kinase signaling pathway have been detected in SCAP. We studied 16 cases of SCAP in the anogenital areas and buttock where this neoplasm is rare and attempted to find out whether SCAP in these sites have different histopathological and molecular biological features. It seems that there is no significant difference between the morphology of anogenital SCAP and SCAP in other locations. Several tumors in our cohort demonstrated features resembling those seen in warts, but HPV DNA was not found in these lesions. On the contrary, we identified DNA of HPV high-risk types in some tumors without HPV-related morphology. Our study confirms the role of HRAS and BRAF V600 mutations in the pathogenesis of SCAP, including SCAP in the anogenital areas and buttock.
Collapse
|
24
|
Mitsui Y, Ogawa K, Takeda M, Kuwahara M, Fukumoto T, Asada H. Grouped apocrine gland component associated with sporadic syringocystadenoma papilliferum: A case report and BRAFV600E mutation analysis of the two components. J Dermatol 2019; 46:e395-e398. [PMID: 31294472 DOI: 10.1111/1346-8138.15020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Yasuhiro Mitsui
- Department of Dermatology, Nara Medical University School of Medicine, Kashihara, Japan
| | - Kohei Ogawa
- Department of Dermatology, Nara Medical University School of Medicine, Kashihara, Japan
| | - Maiko Takeda
- Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan
| | | | | | - Hideo Asada
- Department of Dermatology, Nara Medical University School of Medicine, Kashihara, Japan
| |
Collapse
|
25
|
Garcias-Ladaria J, Cuadrado Rosón M, Pascual-López M. Nevus epidérmicos y síndromes relacionados. Parte 2: Nevus derivados de estructuras anexiales. ACTAS DERMO-SIFILIOGRAFICAS 2018; 109:687-698. [DOI: 10.1016/j.ad.2018.05.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 04/16/2018] [Accepted: 05/23/2018] [Indexed: 02/06/2023] Open
|
26
|
Garcias-Ladaria J, Cuadrado Rosón M, Pascual-López M. Epidermal Nevi and Related Syndromes —Part 2: Nevi Derived from Adnexal Structures. ACTAS DERMO-SIFILIOGRAFICAS 2018. [DOI: 10.1016/j.adengl.2018.07.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
27
|
Kishibe M, Iwasaki T, Takahashi I, Ishida-Yamamoto A. Intracytoplasmic eosinophilic inclusion bodies with embryonic folliculosebaceous-apocrine unit differentiation in syringocystadenoma papilliferum. J Cutan Pathol 2018; 45:923-926. [DOI: 10.1111/cup.13344] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 08/20/2018] [Accepted: 08/23/2018] [Indexed: 02/06/2023]
Affiliation(s)
- Mari Kishibe
- Department of Dermatology; Asahikawa Medical University; Asahikawa Japan
| | - Takeshi Iwasaki
- Department of Dermatology; Asahikawa Medical University; Asahikawa Japan
| | - Ichiro Takahashi
- Department of Dermatology; Kitami Red Cross Hospital; Kitami Japan
| | | |
Collapse
|
28
|
Liau JY, Tsai JH, Huang WC, Lan J, Hong JB, Yuan CT. BRAF and KRAS mutations in tubular apocrine adenoma and papillary eccrine adenoma of the skin. Hum Pathol 2018; 73:59-65. [DOI: 10.1016/j.humpath.2017.12.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 11/17/2017] [Accepted: 12/01/2017] [Indexed: 02/07/2023]
|
29
|
Friedman BJ, Sahu J, Solomides CC, Connolly DM, Lee JB. Contiguous verrucous proliferations in syringocystadenoma papilliferum: A retrospective analysis with additional evaluation via mutation-specific BRAFV600E immunohistochemistry. J Cutan Pathol 2018; 45:212-216. [DOI: 10.1111/cup.13093] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Revised: 11/18/2017] [Accepted: 11/29/2017] [Indexed: 12/19/2022]
Affiliation(s)
- Ben J. Friedman
- Department of Dermatology and Cutaneous Biology; Thomas Jefferson University; Philadelphia Pennsylvania
| | - Joya Sahu
- Department of Dermatology and Cutaneous Biology; Thomas Jefferson University; Philadelphia Pennsylvania
| | - Charalambos C. Solomides
- Department of Pathology, Anatomy and Cell Biology; Thomas Jefferson University; Philadelphia Pennsylvania
| | - Deirdre M. Connolly
- Department of Dermatology and Cutaneous Biology; Thomas Jefferson University; Philadelphia Pennsylvania
| | - Jason B. Lee
- Department of Dermatology and Cutaneous Biology; Thomas Jefferson University; Philadelphia Pennsylvania
| |
Collapse
|
30
|
Saraggi D, Salmaso R, Valentini E, Munari G, Vindigni V, Rugge M, Fassan M, Cerroni L. Pigmented trichoblastoma developed in a sebaceous nevus: HRAS mutation as a common molecular driver. Pathol Res Pract 2017; 213:860-862. [DOI: 10.1016/j.prp.2017.03.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Revised: 03/13/2017] [Accepted: 03/13/2017] [Indexed: 01/27/2023]
|
31
|
Groesser L, Peterhof E, Evert M, Landthaler M, Berneburg M, Hafner C. BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma. J Invest Dermatol 2016; 136:481-6. [PMID: 26802240 DOI: 10.1038/jid.2015.376] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Revised: 09/07/2015] [Accepted: 09/11/2015] [Indexed: 01/13/2023]
Abstract
Pyogenic granuloma (PG) is a common benign vascular skin lesion presenting as a rapidly growing angiomatous papule. The pathogenesis of most sporadic PGs and PGs associated with port wine stains (PWSs) remains elusive. We report that of 10 PGs secondarily arisen on a PWS, 8 showed a BRAF c.1799T>A (p.(Val600Glu)) and 1 a NRAS c.182A>G (p.(Gln61Arg)) mutation. The GNAQ c.548G>A mutation was identified in the PG and in the respective underlying PWS, indicating that PGs originate from cells of the PWS. In contrast to PG, 12 papulonodular lesions, which had developed in the PWSs of seven patients, showed a RAS and BRAF wild-type status. In sporadic PG we identified the BRAF c.1799T>A mutation in 3 of 25, a BRAF c.1391G>A mutation in 1 of 25, and a KRAS c.37G>C mutation in 1 of 25. Mutation-specific immunohistochemical detection of BRAF p.(Val600Glu) confirmed endothelial cells as carriers of the mutation in secondary and sporadic PG. Our study identifies the BRAF c.1799T>A mutation as a major driver mutation in the pathogenesis of, particularly, secondary PG. These data shed light on the hitherto undetermined genetic basis of PG and classify PG as a benign neoplasm.
Collapse
Affiliation(s)
- Leopold Groesser
- Department of Dermatology, University of Regensburg, Regensburg, Germany.
| | - Eva Peterhof
- Department of Dermatology, University of Regensburg, Regensburg, Germany
| | - Matthias Evert
- Institute of Pathology, University of Regensburg, Regensburg, Germany
| | - Michael Landthaler
- Department of Dermatology, University of Regensburg, Regensburg, Germany
| | - Mark Berneburg
- Department of Dermatology, University of Regensburg, Regensburg, Germany
| | | |
Collapse
|
32
|
Liau JY, Lan J, Hong JB, Tsai JH, Kuo KT, Chu CY, Sheen YS, Huang WC. Frequent PIK3CA-activating mutations in hidradenoma papilliferums. Hum Pathol 2016; 55:57-62. [PMID: 27184479 DOI: 10.1016/j.humpath.2016.04.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 04/05/2016] [Accepted: 04/21/2016] [Indexed: 12/12/2022]
Abstract
Hidradenoma papilliferum (HP) is a benign epithelial tumor most commonly seen in the vulva. It is proposed to be derived from the anogenital mammary-like glands and is histologically very similar to the mammary intraductal papilloma (IP). Approximately 60% of mammary IPs have activating mutations in either PIK3CA or AKT1, with each gene accounting for 30% of cases. In this study, we screened the mutation statuses of PIK3CA, AKT1, RAS, and BRAF in 30 HPs. The results showed that activating mutations in either PIK3CA or AKT1 were identified in 20 tumors (67%); 19 tumors had PIK3CA mutations (63%; 13 in exon 20 and 6 in exon 9), and 1 had an AKT1 E17K mutation (3%). BRAF V600E mutation was found in an HP that also had a PIK3CA H1047R mutation. No RAS mutation was found. The mutation status was not correlated with the degree of epithelial cell hyperplasia. We conclude that although there might be site-related variations in the mutation frequencies of PIK3CA and AKT1 genes, HP is histologically and also genetically very similar to the mammary IP, suggesting that HP can be viewed as the extramammary counterpart of mammary IP.
Collapse
Affiliation(s)
- Jau-Yu Liau
- Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10051, Taiwan
| | - Jui Lan
- Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
| | - Jin-Bon Hong
- Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan
| | - Jia-Huei Tsai
- Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10051, Taiwan
| | - Kuan-Tin Kuo
- Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan
| | - Chia-Yu Chu
- Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan
| | - Yi-Shuan Sheen
- Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan
| | - Wen-Chang Huang
- Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
| |
Collapse
|
33
|
Kuentz P, Mignot C, St-Onge J, Duffourd Y, Bonniaud B, Faivre L, Rivière JB, Vabres P. Postzygotic BRAF p.Lys601Asn Mutation in Phacomatosis Pigmentokeratotica with Woolly Hair Nevus and Focal Cortical Dysplasia. J Invest Dermatol 2016; 136:1060-1062. [DOI: 10.1016/j.jid.2016.01.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Revised: 01/04/2016] [Accepted: 01/05/2016] [Indexed: 02/05/2023]
|
34
|
Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. Hum Pathol 2016; 51:25-31. [PMID: 27067779 DOI: 10.1016/j.humpath.2015.12.015] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Revised: 12/06/2015] [Accepted: 12/10/2015] [Indexed: 12/17/2022]
Abstract
Porocarcinomas are a rare eccrine carcinoma with significant metastatic potential. Oncogenic drivers of porocarcinomas have been underexplored, with PIK3CA-activating mutation reported in 1 case. We analyzed 5 porocarcinomas by next-generation sequencing using the DNA component of the Oncomine Comprehensive Assay, which provides data on copy number changes and mutational events in 126 cancer-relevant genes through multiplex polymerase chain reaction. We detected an average of 3.3 high-confidence nonsynonymous mutations per tumor (range, 1-6), including a spectrum of oncogenic activation and tumor suppressor inactivation events. Tumor suppressor mutations included TP53 (4/5, 80%), RB1 (3/5, 60%), ATM (2/5, 40%), ARID1A (1/5, 20%), and CDKN2A (1/5, 20%). In 4 (80%) of 5 tumors, at least 1 potential oncogenic driver was identified. Activating HRAS mutations were detected in 2 (40%) of 5, including G13D and Q61L hotspot mutations. Mutations of EGFR were identified in 2 (40%) of 5; these mutations have been previously reported in cancer but did not affect classic activation hotspot sites. EGFR and HRAS mutations were mutually exclusive. HRAS mutations were detected by targeted sequencing in a minority of benign eccrine poromas (2/17; 11.7%), suggesting that HRAS activation may rarely be an early event in sweat gland neoplasia. Together, our data suggest roles for HRAS and EGFR as drivers in a subset of poroma and porocarcinoma. TP53 and RB1 inactivation events are also likely to contribute to tumorigenesis. These findings suggest that porocarcinomas display diversity with respect to oncogenic drivers, which may have implications for targeted therapy in metastatic or unresectable cases.
Collapse
|
35
|
Hsu CK, Saito R, Nanda A, Rashidghamat E, Al-Ajmi H, Lee JYY, Hide M, McGrath JA. Systematised naevus sebaceus resulting from post-zygotic mutation in HRAS. Australas J Dermatol 2015; 58:58-60. [DOI: 10.1111/ajd.12399] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 08/26/2015] [Indexed: 12/20/2022]
Affiliation(s)
- Chao-Kai Hsu
- St John's Institute of Dermatology; King's College London, Guy's Hospital; London UK
- Department of Dermatology, National Cheng Kung University Hospital, ; National Cheng Kung University; Tainan Taiwan
- Institute of Clinical Medicine, College of Medicine; National Cheng Kung University; Tainan Taiwan
| | - Ryo Saito
- St John's Institute of Dermatology; King's College London, Guy's Hospital; London UK
- Department of Dermatology; Hiroshima University; Hiroshima Japan
| | - Arti Nanda
- As' ad Al-Hamad Dermatology Center; Al-Sabah Hospital; Kuwait Kuwait
| | - Ellie Rashidghamat
- St John's Institute of Dermatology; King's College London, Guy's Hospital; London UK
| | - Hejab Al-Ajmi
- As' ad Al-Hamad Dermatology Center; Al-Sabah Hospital; Kuwait Kuwait
| | - Julia Yu-Yun Lee
- Department of Dermatology, National Cheng Kung University Hospital, ; National Cheng Kung University; Tainan Taiwan
| | - Michihiro Hide
- Department of Dermatology; Hiroshima University; Hiroshima Japan
| | - John A McGrath
- St John's Institute of Dermatology; King's College London, Guy's Hospital; London UK
| |
Collapse
|
36
|
Watanabe Y, Shido K, Niihori T, Niizuma H, Katata Y, Iizuka C, Oba D, Moriya K, Saito-Nanjo Y, Onuma M, Rikiishi T, Sasahara Y, Watanabe M, Aiba S, Saito R, Sonoda Y, Tominaga T, Aoki Y, Kure S. Somatic BRAF c.1799T>A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities. Am J Med Genet A 2015; 170A:189-94. [DOI: 10.1002/ajmg.a.37376] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Accepted: 08/30/2015] [Indexed: 01/14/2023]
Affiliation(s)
- Yuko Watanabe
- Department of Pediatrics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Kosuke Shido
- Department of Dermatology; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Tetsuya Niihori
- Department of Medical Genetics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Hidetaka Niizuma
- Department of Pediatrics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Yu Katata
- Department of Pediatrics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Chie Iizuka
- Department of Pediatrics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Daiju Oba
- Department of Medical Genetics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Kunihiko Moriya
- Department of Pediatrics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Yuka Saito-Nanjo
- Department of Pediatrics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Masaei Onuma
- Department of Pediatrics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Takeshi Rikiishi
- Department of Pediatrics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Yoji Sasahara
- Department of Pediatrics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Mika Watanabe
- Department of Pathology; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Setsuya Aiba
- Department of Dermatology; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Ryuta Saito
- Department of Neurosurgery; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Yukihiko Sonoda
- Department of Neurosurgery; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Teiji Tominaga
- Department of Neurosurgery; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Yoko Aoki
- Department of Medical Genetics; Tohoku University School of Medicine; Sendai Miyagi Japan
| | - Shigeo Kure
- Department of Pediatrics; Tohoku University School of Medicine; Sendai Miyagi Japan
| |
Collapse
|
37
|
|